SCHEMBL9798992

SCHEMBL9798992

c1ccc(NCc2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 7/20 0.68
FFAR4 Q5NUL3 2/20 0.64
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
PTPRF P10586 1/20 0.56
PTPN2 P17706 1/20 0.56
PTPN1 P18031 1/20 0.56
PTPN11 Q06124 1/20 0.56
HTT P42858 1/20 0.55
HDAC1 Q13547 1/20 0.54
HIF1A Q16665 1/20 0.51
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19006636 0.95 FFAR1 (0.73) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL5362592 0.91 FFAR1 (0.68) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL2065031 0.91 CYP1A2 (0.69) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL10756655 0.88 HTT (0.69) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL25760803 0.88 FFAR1 (0.63) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL17448681 0.88 HTT (0.75) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL19091942 0.86 FFAR1 (0.63) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL11512045 0.86 HTT (0.79) FFAR1FFAR4MEN1KMT2ACYP1A2
SCHEMBL11509316 0.86 FFAR1 (0.68) FFAR1FFAR4MEN1KMT2AHTT
SCHEMBL11510992 0.86 FFAR1 (0.63) FFAR1FFAR4MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114340636-A Method of treatment 细胞内治疗公司 2022-04-12 CN claimed
CN-113194955-A New use 细胞内治疗公司 2021-07-30 CN claimed
CN-112189013-A Organic compounds 细胞内治疗公司 2021-01-05 CN claimed
CN-102238872-A Organic compounds INTRA CELLULAR THERAPIES INC 2011-11-09 CN claimed
CN-102232077-A Organic compounds INTRA CELLULAR THERAPIES INC 2011-11-02 CN claimed
CN-102231953-A Organic compounds INTRA CELLULAR THERAPIES INC 2011-11-02 CN claimed
WO-2023096225-A1 HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE AND COMPOSITION FOR FORMING ORGANIC MATERIAL LAYER, COMPRISING SAME 엘티소재주식회사 2023-06-01 WO disclosed
CN-115925555-A Selective hydrogenation reduction method of alpha, beta-unsaturated imine 化学与精细化工广东省实验室 2023-04-07 CN disclosed
CN-114340636-A Method of treatment 细胞内治疗公司 2022-04-12 CN disclosed
US-11214538-B2 Farnesoid X receptor agonists and uses thereof METACRINE, INC. (US) 2022-01-04 US disclosed
CN-113194955-A New use 细胞内治疗公司 2021-07-30 CN disclosed
US-20210032195-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2021-02-04 US disclosed
CN-112189013-A Organic compounds 细胞内治疗公司 2021-01-05 CN disclosed
US-5015762-A Alkoxy substituted ureas as herbicides BASF AKTIENGESELLSCHAFT (DE) 1991-05-14 US disclosed
EP-0041145-B1 ARALKYL-PHENYL UREAS AND THEIR HERBICIDAL COMPOSITIONS BASF Aktiengesellschaft (DE) 1984-12-19 EP disclosed
US-4422871-A Aralkylphenylureas and herbicides containing these BASF AKTIENGESELLSCHAFT (DE) 1983-12-27 US disclosed
EP-0041145-A2 Aralkyl-phenyl ureas and their herbicidal compositions BASF Aktiengesellschaft (DE) 1981-12-09 EP disclosed
US-4152452-A N-BENZYLANILINE AND DERIVATIVES WILLIAM H. RORER, INC. (US) 1979-05-01 US disclosed
US-4076530-A Dry photographic copying method for producing Te images FUJI PHOTO FILM CO., LTD. (JA) 1978-02-28 US disclosed
US-4062685-A ORGANO-TELLURIUM COMPOUND FUJI PHOTO FILM CO., LTD. (JA) 1977-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032195-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF NR1H4, NR1H2, NR1H3 FFAR1 45/4885FFAR4 57/4885MEN1 2725/4885
US-11214538-B2 Farnesoid X receptor agonists and uses thereof NR1H4, NR1H2, NR1H3 FFAR1 45/4885FFAR4 57/4885MEN1 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.